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Dynamic prediction of survival in cystic fibrosis: 
A landmarking analysis using UK patient registry data 
 
ABSTRACT 
Background 
Cystic fibrosis (CF) is an inherited, chronic, progressive condition affecting around 10,000 
individuals in the UK and over 70,000 worldwide. Survival in CF has improved considerably 
over recent decades and it is important to provide up to date information on patient prognosis. 
Methods 
The UK Cystic Fibrosis Registry is a secure centralized database, which collects annual data 
on almost all CF patients in the UK. Data from 43,592 annual records from 2005-2015 on 6181 
individuals were used to develop a dynamic survival prediction model that provides 
personalised estimates of survival probabilities given a patient’s current health status using 16 
predictors. The model was developed using the landmarking approach, giving predicted 
survival curves up to 10 years from ages 18 to 50. Several models were compared using cross-
validation. 
Results 
The final model has good discrimination (C-indexes 0.873, 0.843, 0.804 for 2-, 5-, 10-year 
survival prediction) and low prediction error (Brier scores 0.036, 0.076, 0.133). It identifies 
individuals at low and high risk of short- and long-term mortality based on their current status. 
For patients aged 20 during 2013-2015, for example, over 80% had a greater than 95% 
probability of 2-year survival and 40% were predicted to survive 10 years or more.  
Conclusions 
Dynamic personalised prediction models can guide treatment decisions and provide 
personalised information for patients. Our application illustrates the utility of the landmarking 
approach for making the best use of longitudinal and survival data and shows how models can 
be defined and compared in terms of predictive performance. 
 
Keywords: Cox regression; Cystic fibrosis; Dynamic prediction; Landmarking; Longitudinal 
data; Patient registry; Personalised prediction; Survival.  
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INTRODUCTION 
 
Cystic fibrosis (CF) is an inherited, chronic, progressive condition affecting around 10,000 
individuals in the UK and over 70,000 worldwide.1,2 In the UK CF affects  about 1 in 2500 live 
births 3. Children with CF are generally diagnosed in the first few months of life, with universal 
newborn screening implemented in 2007 in the UK, though some people with milder 
phenotypes are diagnosed into adulthood.4 
 
Survival in CF has improved considerably over recent decades. Of individuals born around 
1970, over half died before reaching their mid-to-late teens.5,6 By contrast, the estimated 
median survival age for a person born with CF today in the UK is 48 for males and 44 for 
females.1,7 It is important to be able to provide patients with up to date information on their 
prognosis, and to provide clinicians with information to guide treatment decisions, including 
listing for lung transplantation. 
 
Data from national CF patient registries with longitudinal measures of health status and long 
term follow-up have created the opportunity to develop models for predicting survival based 
on individual characteristics.8,9 Although there have been many studies of factors associated 
with survival in CF (see Buzetti et al.10 and MacNeill3 for overviews),  fewer have focused on 
prediction. We identified three models for survival prediction in UK patients, but all are based 
on small samples or subsets of patients.11–13 Survival prediction models in CF have been 
developed using national patient registries by Liou et al.14 and Mayer-Hamblett et al.15 (United 
States), Aaron et al.16 (Canada), and Nkam et al.17 (France). Until recently there have been no 
detailed studies of survival using the UK CF Registry. Keogh et al.18 provided estimates of 
survival using UK CF Registry data given the baseline characteristics of sex, genotype and age 
of diagnosis. In this paper we develop a model for personalised prediction of survival in the 
UK making use of time-dependent measures of health status. 
 
The aims of this article are twofold. Our first aim was to use data from the UK CF Registry to 
develop a dynamic survival prediction model that provides estimates of the probability of short-
term, mid-term and long-term survival given a patient’s current and past health status.19  We 
used the landmarking approach applied to UK CF Registry data on adults from 2005-2015, 20,21 
giving predicted survival curves up to 10 years from each landmark age,which can be any age 
post-diagnosis. The model therefore provides predictions for individuals living with the CF 
who already survived to a given age. The model is dynamic in that it enables predictions to be 
updated over time, using updated measures of time-dependent predictors alongside a patient’s 
current age. Our second aim was to provide an example for other researchers of how to develop 
a dynamic prediction model using landmarking, illustrating the utility of this approach for 
making the best use of longitudinal and survival data, and showing how different models can 
be defined and compared in terms of their predictive performance. 
 
METHODS 
 
Design and data source 
 
We undertook a landmarking analysis using data from the UK CF Registry, a national, secure 
database sponsored and managed by the Cystic Fibrosis Trust.19 The Registry was established 
in 1995 and records demographic data and longitudinal health data on nearly all people with 
CF in the UK, to date capturing data on over 12,000 individuals. NHS Research Ethics approval 
has been granted for the collection of data into the Registry. Each patient or their parent 
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provided written informed consent for collection of data in the Registry and use of 
pseudonymized data in research. In the UK, CF patients are treated in specialist centres and 
data for the Registry are collected in a standardized way at designated (approximately) annual 
visits. Data collected cover over 250 variables in several domains, alongside mortality data. 
We restricted our analyses to a set of 17 variables (Table 1) recorded routinely in the Registry 
and previously found to be associated with survival, based on a review of the literature. 
3,10,11,13,15–17,22–28 This set consists of  3 baseline variables – sex; genotype (F508del alleles); 
age of diagnosis  -  calendar year, and 13 internal time-dependent variables - forced expiratory 
volume in 1 second as percentage predicted  (FEV1%); forced ventricular capacity as 
percentage predicted (FVC%); height; weight; infection status for four organisms 
(Pseudomonas aeruginosa, Staphylococcus  aureus, Burkholderia cepacia, Methicillin-
resistant Staphylococcus aureus (MRSA)); CF-related diabetes (CFRD); pancreatic 
insufficiency; days in hospital on intravenous (IV) antibiotics; days at home on IV antibiotics; 
and other hospitalisation. FEV1% and FVC% were calculated using the global lung initiative 
(GLI) equations.29 We investigated using BMI instead of weight and height, but found that 
models including weight and height separately were better fitting, based on Akaike’s 
Information Criterion.30 The two variables for days on IV antibiotics are used as surrogate 
indicators for pulmonary exacerbations.31,32 
Analyses are based on follow-up during the study period 2005-2015, so that some individuals 
have at least 10 years of follow-up, enabling estimation of survival up to 10 years. Individuals 
who died or were lost-to-follow-up before 2005 were therefore excluded. In order to focus on 
adults, we only used data on individuals from age 18 onwards during the study period.  
The landmarking approach 
The landmarking approach for dynamic prediction of survival was first described by van 
Houwelingen.20 A detailed account is provided by van Houwelingen and Putter.21 In brief, at a 
given age (a ‘landmark age’) from which a prediction is to be made, the data are restricted to 
individuals who have not yet had the event (in this case, death) or been censored. Values of 
predictor variables available up to the landmark age are used as covariates in a model for the 
probability of survival up to some time horizon, conditional on survival to the landmark age. 
Typically, the focus is on survival to a single time horizon (𝑡ℎ𝑜𝑟), e.g. two years after the 
landmark age (𝑡ℎ𝑜𝑟 = 2), and censoring is imposed at 𝑡ℎ𝑜𝑟 so that only events up to that time 
are used in the survival analysis. For a chronic condition like CF, however, it is of interest to 
study survival to several time horizons. We use the Cox model and its extensions to model 
survivor curves up to 10 years after each landmark age.  
Landmark data sets were created from landmark ages 𝑙 = 18, … ,50 (Supplementary Figure 1, 
Supplementary Section S1). Data on individuals aged over 50 are sparse. The 𝑙th landmark 
data set included all individuals known to be alive at age 𝑙 during 2005-2015, who had not 
received a transplant prior to age 𝑙, who were diagnosed with CF before age 𝑙, and who joined 
the Registry before age 𝑙. Individuals lost to follow up before age 𝑙 were excluded. We excluded 
people who received a transplant prior to age 𝑙  because the variables of importance for survival 
in transplanted patients are likely to be quite different from those of importance for 
untransplanted individuals.33 Individuals transplanted after age 𝑙 were included in the 𝑙th 
landmark data set and their deaths were counted as events in the survival analysis. The 
predictors in the 𝑙th landmark data set were the three baseline variables, calendar year and 
variables that summarise the measurements of the remaining 13 time-dependent predictors up 
to age 𝑙. We summarise time-dependent measurements in two ways. Firstly, we used the most 
recently available measure at time 𝑙 of each time-dependent variable. This ‘last-observation-
carried-forward’ (LOCF) approach was used in the original descriptions of landmarking.20,21 
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Secondly, we fitted a mixed effects model to data available on time-dependent variables up to 
the landmark age and used the resulting fitted values and slopes at the landmark age as 
predictors, since some studies have suggested that this makes better use of the data than 
LOCF.34–36 We implemented this two-stage landmarking approach by fitting a multivariate 
mixed model to three continuous time-dependent variables - FEV1%, FVC%, weight - up to 
each landmark age (Supplementary Section S2, Supplementary Table 2).  
A single stacked data set was created, by stacking the 33 landmark data sets (𝑙 = 18, … ,50), 
for use in pooled models (see below). Many individuals appear multiple times in the stacked 
data set because they are eligible for several landmark data sets. Robust standard errors were 
used to account for this. 
Model building 
The aim was to obtain a dynamic prediction model that performs well for predicting 2-, 5- and 
10-year survival from each landmark age. We considered a number of multivariable Cox 
models (Table 2) before selecting a final model based on assessment of their predictive 
performance. Further details on the models and on how predicted survival probabilities were 
obtained are given in Supplementary Section S2.  
Models 1-5 use the LOCF values for the 13 time-dependent predictors. We began by fitting 
separate survival models from each landmark age 𝑙 (Model 1).  An alternative is to fit a pooled 
model (a ‘supermodel’) to the stacked data set. The simplest supermodel (Model 2) allowed a 
separate baseline hazard for each landmark age, but assumed common predictor coefficients 
across all landmark ages. Models 1 and 2 were initially fitted using a time horizon of 10 years 
(𝑡ℎ𝑜𝑟 = 10), which enables us to obtain predicted survival probabilities for any time up to 10 
years after the landmark age. We also investigated whether 2- and 5-year survival could be 
better predicted by using 𝑡ℎ𝑜𝑟 = 2 and 𝑡ℎ𝑜𝑟 = 5 respectively. One might expect to better 
predict 2-year survival (for example) by using  𝑡ℎ𝑜𝑟 = 2 instead of 𝑡ℎ𝑜𝑟 = 10 because the 
effects of time-dependent variables are expected to change less over 2 years than 10 years. 
However, this was not found to be the case and all subsequent models were fitted with 𝑡ℎ𝑜𝑟 =
10. Since we found that the supermodel gave better predictive performance, subsequently 
investigated models were all extensions of Model 2.  
Model 3 allows predictor coefficients (log hazard ratios) to vary smoothly with 𝑙. Model 4 
allows the predictor coefficients to vary with time since landmark (𝑡 − 𝑙). Model 5 uses a 
common baseline hazard with the impact of landmark age on the hazard modelled using 
regression terms. Model 6 extends Model 2 by using the fitted value and slope at each landmark 
age for each of FEV1%, FVC% and weight from the multivariate mixed models (one for each 
landmark age) as additional time-dependent predictors (as well as the LOCF values). By 
incorporating slopes from the mixed models, the prediction model includes information about 
trajectories of FEV1%, FVC% and weight up to each landmark age. For height and the 
categorical time-dependent variables we used LOCF in all models. In all models continuous 
variables were assumed to have linear effects; modelling them using splines brought negligible 
changes in predictive performance. 
Model assessment 
The data were divided into a “training+validation” (TV) set - an 80% random sample of the 
stacked data, stratified by landmark age - and a “holdout” set - the remaining 20%.37 The TV 
set was used for model development and assessment. Details are given in Supplementary 
Section S3. 
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The predictive performances of different models were compared in terms of discrimination, 
using the C-index,38–40 and prediction error, using the Brier score.41,42 C-indexes and Brier 
scores were calculated separately for each landmark age for prediction of 2-, 5- and 10-year 
survival. We also obtained overall C-indexes and Brier scores across landmark ages for 2-, 5- 
and 10-year survival. A Monte-Carlo cross-validation procedure was used to avoid over-
optimism about predictive performance.43  
The final model was selected as that with the best predictive performance, though where several 
models had similar performance we favoured a simpler model. The final model was applied to 
the holdout data to estimate its performance in a new set of individuals. Lastly, the final model 
was fitted to the complete data and is reported in full for use by other researchers. 
All analyses were performed using R. Supplementary Section S4 provides details on software. 
RESULTS 
Data overview 
The stacked data set has 43,592 rows and 6181 unique individuals, of whom 931 died within 
10 years of follow-up (Supplementary Section S2).  Censoring is entirely due to the end of 
follow-up at the end of 2015, rather than loss-to-follow-up.  Many individuals appear in 
multiple landmark data sets. Supplementary Figure 1 illustrates how the data arose. Figure 1 
summarises the number of individuals in each landmark data set, and the number of deaths 
within 2, 5 and 10 years of each landmark age. Supplementary Table 1 gives more detailed 
information. Table 3 summarises the predictors at landmark ages 20, 30, 40 and 50.  
Comparison of dynamic prediction models 
Overall C-indexes and Brier scores from Models 1-6 are shown in Table 4. Model 1, in which 
separate models were fitted from each landmark, gave overall C-Indexes of 0.841, 0.811 and 
0.771 for 2-, 5- and 10-year survival respectively, and corresponding Brier scores of 0.038, 
0.082 and 0.147, indicating better predictive performance for short-term survival. A 
supermodel fitted across landmark ages (Model 2) brought gains in terms of both 
discrimination and prediction error. The C-indexes for 2-, 5- and 10-year survival increased to 
0.873, 0.843 and 0.804, and the Brier scores reduced to 0.036, 0.076, and 0.133. Landmark-
age-specific C-indexes and Brier scores (Supplementary Figures 2 and 3) show that the gains 
in predictive performance from using the supermodel are particularly important for older 
landmark ages. This is because there are less data at those ages and hence more to be gained 
by drawing strength from other landmark ages by using a supermodel.  
Allowing the predictor coefficients to depend on landmark age in a smooth way (Model 3) 
resulted in very similar results to Model 2. Including time-varying coefficients for all predictors 
(Model 4) resulted in worse predictive performance compared with Model 2. Restricting the 
time-varying coefficients to FEV1%, the strongest predictor, gave very similar results to Model 
2. Using splines instead of a linear form for the time-varying coefficients did not bring any 
improvements.  This lack of advantage of using time-varying coefficients in part reflects our 
finding that using a shorter time-horizon (𝑡ℎ𝑜𝑟 = 2 or 5) did not improve prediction. Using a 
common baseline hazard, with the impact of landmark age modelled using regression terms 
(Model 5), resulted in considerably worse predictive performance than Model 2.  
Inclusion of the fitted values and slopes from mixed models for FEV1%, FVC% and weight in 
addition to the LOCF terms brought small improvements in the C-indexes and Brier scores. 
Further investigations found that including the mixed model terms without the corresponding 
LOCF terms resulted in worse predictive performance than Models 2 and 6.  
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Final model 
Based on the above comparisons, we selected Model 2 as the final model: increasing model 
complexity had not resulted in improvements in predictive performance, suggesting a trade-off 
between increased complexity and estimation of more parameters. While there were small 
gains in predictive performance from using mixed models for three of the continuous variables 
(Model 6), these were fairly negligible and came at the expense of a significantly more 
complicated procedure for obtaining predicted survival probabilities. Also, Model 2 requires 
only the most recent values of predictors at the landmark age, while the mixed modelling 
approach (Model 6) requires a series of measures up to the landmark age. Furthermore, Model 
2 is more straightforward to explain and report to potential users.  
Figure 2 shows calibration plots for the final model for landmark ages 20, 30, 40, and 50, which 
compare model-based predicted survival probabilities with ‘observed’ probabilities. For 2-year 
and 5-year survival the points lie close to the line of equality, indicating good agreement 
between predicted probabilities from the model and the observed probabilities. There is also 
good agreement for 10-year survival for landmark ages 20, 30 and 40. At landmark age 50 the 
agreement between predicted and observed 10-year survival probabilities is less good, which 
may be partly due to sparse data at the older ages. These results indicate that the model is well 
calibrated for prediction of 2- and 5-year survival from all landmark ages, and for 10-year 
survival at least up to age 40.  
Application in the holdout data 
The final model was fitted to the complete TV data and applied to the holdout data to 
demonstrate its use in practice. The resulting overall C-indexes for 2-, 5- and 10-year survival 
were 0.854, 0.843, and 0.815. The corresponding overall Brier scores were 0.034, 0.077, and 
0.125, representing percentage reductions in prediction error against the Kaplan-Meier 
estimates of survival probabilities of 12.22%, 20.92%, and 23.86%. Supplementary Table 3 
summarises observed survival within groups defined by the predicted survival probabilities.   
 
Full model specification 
The final model was fitted to the complete data (the TV and holdout data combined). Estimated 
baseline hazards ℎ0𝑙(𝑡) are given in Supplementary Materials (Section S5); in combination 
with the regression coefficients in Table 5, these provide a full specification of the dynamic 
prediction model. Higher FEV1%, FVC% and weight were strongly associated with reduced 
hazard. B. cepacia infection, CFRD, and more hospital IV days were strongly associated with 
increased hazard. Using the final model fitted to the complete data, we calculated 2-, 5- and 
10-year predicted survival probabilities from ages 20, 30, 40 and 50 for individuals in the CF 
Registry at these ages during the most recent 3-year period for which data were available (2013-
2015). Figure 3 and Supplementary Figures 4-6 illustrate typical profiles of individuals within 
groups defined by predicted survival probabilities and show corresponding predicted survivor 
curves. Figure 4 shows the distributions of the predicted probabilities.  At age 20, over 80% of 
individuals had a greater than 95% probability of 2-year survival, and over 35% of 10-year 
survival. At landmark ages 30, 40 and 50, over 75% of individuals had a greater than 90% 
probability to survive 2 years, and over 50% had a greater than 90% probability to survive 5 
years. These plots further demonstrate how the model could be used to identify patients at 
greatest risk and those with a good prognosis.  
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DISCUSSION 
We have developed a model for dynamic prediction of survival for people with CF in the UK 
using UK CF Registry data. We used a landmarking approach applied to CF data for the first 
time, making efficient use of the longitudinal data, by using information from the same 
individual at several ages and incorporating updated measures of health status. The model 
enables predictions of survival up to 10 years for adults with CF aged up to 50 and can be used 
to identify high risk patients, making use of information on 16 variables. There are several 
potential roles for practical use of the model, including  for guiding treatment decisions,  
informing referral for lung transplantation44, and  providing personalised information going far 
beyond the population-level statistics that are currently available, which is important for 
patients (Keogh 2017, unpublished manuscript).  
We have outlined a systematic approach to development of a dynamic prediction model using 
landmarking, incorporating the assessment of models of different levels of complexity by 
comparing their predictive performance. There have been relatively few practical applications 
of landmarking.34,45,46 Unlike previous applications we have provided predicted survival curves 
instead of focusing on a single time-horizon, and we provided results on model performance 
for 2-, 5- and 10-year survival. Prediction of long-term survival is of particular relevance for 
chronic conditions such as CF, and ours is the first prediction model based on UK CF Registry 
data. Of the three earlier prediction models using national patient registry data , two used 
logistic regression,14,17 and so did not handle censoring, and did not make efficient use of the  
longitudinal data. Aaron et al.16 used a stochastic process model. No previous prediction 
models in CF have considered survival to more than one time point or beyond 5 years.12–17,22,25    
Comparisons of predictive performance with models obtained in other populations are 
summarised in Supplementary Section S Future work may result in new models for the UK 
population that could be compared with ours and it is important that similar measures of 
predictive performance are presented across studies to facilitate comparisons. We used the 
landmarking approach to perform dynamic prediction. An alternative approach uses joint 
modelling of the longitudinal and survival processes.47–49 Landmarking had several strengths 
over joint modelling for this application. Firstly, landmarking enabled us to handle transplanted 
individuals in a straightforward way. We excluded previously transplanted individuals at each 
landmark age, but retained post-transplant deaths in the data set for estimating survival after 
each landmark age. Our predictions therefore refer to individuals who are untransplanted at the 
time of making the prediction. Development of a prediction model for post-transplant survival 
is an area for further work. It is not clear how transplanted individuals should be handled in the 
joint modelling approach, especially using readily available software. Secondly, the set of 
predictors included 12 time-dependent variables of different types (continuous, categorical, 
binary). Although joint modelling has recently been extended for use with multivariate 
longitudinal outcomes,50 its feasibility for use with a large number of such variables of different 
types remains in question. The two-stage landmarking approach,34–36 which used mixed models 
for continuous time-dependent predictors (Model 6), did not result in material gains compared 
with using the LOCF method. Landmarking also has the advantage of being based on methods, 
notably Cox regression, that are familiar to a clinical audience, which facilitates its explanation. 
Recent comparisons of landmarking with joint modelling using simulation studies have tended 
to find joint modelling to perform slightly better than landmarking. 35,36,51 However, they have 
focused on simple simulation scenarios favouring the joint model and have not considered 
landmark supermodels.  
A major strength of our study is the use of the UK CF Registry data to create the dynamic 
prediction model. The Registry collects longitudinal data on almost all UK CF patients, and 
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the structured data collection means there is little missing data and little loss-to-follow-up. A 
limitation is that predicted survival probabilities cannot account for improvements in survival 
that are not yet known about, e.g. due to new treatments.52,53 However, treatments manifest 
themselves in measures of health status, and so it is likely that the prediction model could still 
apply. That is, the distribution of health status measures in the CF population may change, but 
the associations of health status measures with survival remain the same. The standardized 
format of the Registry data collection means that the model could be assessed and updated if 
necessary after a few years.  
We selected a set of predictors previously associated with survival in CF and collected 
routinely in the Registry.3,10 FEV1% is the strongest predictor, though predictive performance 
is improved by incorporating the additional variables (Supplementary Table 4).  Further 
investigations using variable selection techniques tended to result in a model containing most 
of the variables. Extensions of variable selection techniques to the context of dynamic 
prediction remains an area for further methodological work. There are many other variables in 
the Registry and an area for further work is to investigate whether using additional variables 
could improve predictive performance. We took the decision not to use data on treatment use 
as predictors. As noted above, the impact of treatments on survival is expected to manifest 
primarily via the health status measures used as predictors. Further investigations also found 
that adding information on use of two treatments did not materially improve prediction 
(Supplementary Table 4). Furthermore, the models created in this work are designed with 
prediction in mind and the estimated coefficients associated with the predictor variables do not 
necessarily represent causal effects. Inclusion of treatment variables could create danger of 
misinterpretation of the impacts of treatment on survival prediction curves as causal effects, 
which could result in inappropriate withholding of treatment if treatment is (non-causally) 
associated with worse prognosis. Estimation of  treatment effects using patient registry data is 
an area of growing interest, 54,55 but involves a separate question from that focused on in this 
paper.  
Our model is for adults with CF. There are relatively few deaths in CF patients aged under 18 
in the UK and different variables may be important for survival prediction in children.12,56 We 
restricted to predictions for adults aged up to 50 because the data above age 50 are sparse. 
Investigations into the health of older people with CF are of interest.  
In summary we have developed a novel landmarking model for dynamic prediction of survival 
for people with CF in the UK. Further work involves the practical implementation of our model 
in a form suitable for use by clinicians, potentially as an add-on to patient information that can 
already be viewed via the Registry interface. In addition, it is important that patients and care-
givers are supported to interpret personalised survival predictions.57–59 
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Table 1. Variables considered as predictors. All are time-dependent except the ‘baseline 
variables’. 
Variable category Variables Description Further information 
    
Baseline variables Sex Male (0), Female (1)  
 Genotype F508del: Homozygous 
F508del: Heterozygous 
F508del: No copies 
 
 Age of diagnosis In years.  
    
Calendar year Calendar year 2005-2015 (coded as 0-10)  
    
Lung function FEV1%  FEV1% predicted, obtained using 
GLI equations. 
Measured at the annual review visit. 
 FVC% FVC% predicted, obtained using 
GLI equations. 
    
Height and weight Weight Kilograms (kg) 
Measured at the annual review visit. 
 Height Centimetres (cm) 
    
Microbiology Pseudomonas 
aeruginosa 
No (0), Yes (1) 
Any finding based on microbiology 
results since the last annual review. 
 Burkholderia cepacia  No (0), Yes (1) 
 Staphylococcus aureus No (0), Yes (1) 
 Methicillin-resistant 
Staphylococcus aureus 
(MRSA) 
No (0), Yes (1) 
    
Complications Pancreatic 
insufficiencya 
No (0), Yes (1) 
All -in the year prior to the annual 
review. 
 CF related diabetesa No (0), Yes (1) 
 Number of hospital IV 
daysb 
0 days (reference category) 
1-14 days 
15-28 days 
29+ days 
 Number of home IV 
daysb 
0 days (reference category) 
1-14 days 
15-28 days 
29+ days 
 Hospitalisation (not for 
IVs) 
No (0), Yes (1) 
a Once an individual was recorded as being pancreatic insufficient (“Yes” (1)) they were considered to be pancreatic 
insufficient at all subsequent time points.  Once an individual was recorded as having CFRD (“Yes” (1)) they were 
considered to have CFRD at all subsequent time points.   
b Number of hospital and home IV days are used as surrogate indicators of pulmonary exacerbations. 
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Table 2. Summary of dynamic prediction models investigated. In all analyses the timescale is 
age (𝑡). Landmark age is denoted 𝑙. For models 1 and 2, using age as the time scale or time-
since-landmark as the timescale are exactly equivalent. 
 
Model Form of the log hazard: log ℎ𝑙(𝑡|𝑋(𝑙), 𝑋
∗(𝑙), 𝑍) Description 
   
Model 1 log ℎ0𝑙(𝑡) + 𝛽𝑙
𝑇𝑋(𝑙) + 𝛾𝑙
𝑇𝑍, 𝑙 = 1, … , 𝐿  Separate model fitted at each landmark age 
   
Model 2 log ℎ0𝑙(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍 Supermodel with separate baseline hazards for 𝑙 = 1, … , 𝐿 
and common predictor coefficients across landmark ages.  
   
Model 3 log ℎ0𝑙(𝑡) + 𝛽(𝑙)
𝑇𝑋(𝑙) + 𝛾(𝑙)𝑇𝑍  Supermodel with separate baseline hazards for 𝑙 = 1, … , 𝐿 
and predictor coefficients modelled as a function of 
landmark age 𝑙. 
   
Model 4 log ℎ0𝑙(𝑡) + 𝛽(𝑡 − 𝑙)
𝑇𝑋(𝑙) + 𝛾(𝑡 − 𝑙)𝑇𝑍  Supermodel with separate baseline hazards for 𝑙 = 1, … , 𝐿 
and time-varying predictor coefficients, but common 
across landmark ages. 
   
Model 5 log ℎ0(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍 + 𝑓(𝑙; 𝛿) Supermodel with an overall baseline hazard, common 
predictor coefficients across landmark ages, and landmark 
effects 𝑓(𝑙; 𝛿). 
   
Model 6 log ℎ0𝑙(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍 + 𝜃𝑇𝑋∗(𝑙) As in Model 2, but with additional predictors 𝑋∗(𝑙) from 
the multivariate mixed model. 
ℎ𝑙(𝑡|𝑋(𝑙), 𝑋
∗(𝑙), 𝑍): Hazard at time 𝑡 given 𝑋(𝑙), 𝑍 and 𝑋∗(𝑙), and given eligibility for the 𝑙th landmark data set 
(Supplementary Section S1).  
ℎ0𝑙(𝑡): Baseline hazard at time 𝑡 given eligibility for the 𝑙th landmark data set (Supplementary Section S1)..  
𝑍: Vector of baseline predictors (sex, genotype and age of diagnosis). 
𝑋(𝑙): Vector of the LOCF values at landmark age 𝑙 for time-dependent predictors (calendar year, FEV1%, FVC%, weight, 
height, CFRD. pancreatic insufficiency, P. aeruginosa, B. cepacia, S. aureus, MRSA, non-IV hospitalization, number of IV 
days). 
𝑋∗(𝑙): Vector of predicted values and slopes for FEV1%, FVC% and weight from a multivariate mixed model. 
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Table 3. Descriptive statistics at landmark ages 20, 30, 40 and 50. Summaries are given as the number (N) and percent for categorical variables and as median and 
interquartile range (IQR) for continuous variables.  
Variable  Landmark age 20 Landmark age 30 Landmark age 40 Landmark age 50 
  N % N % N % N % 
Sex Male  1443   52.9   863   56.3   385   59.8   160   60.8   
 Female  1283   47.1   670   43.7   259   40.2   103   39.2   
          Genotype 2 copies  1549   56.8   820   53.5   263   40.8   87   33.1   
 1 copy  956   35.1   567   37.0   312   48.4   141   53.6   
 Other  221   8.1   146   9.5   69   10.7   35   13.3   
          Age of diagnosis (years) Median (IQR)  0.3   (0.1, 2.0)   0.7   (0.1, 3.5)   2.0   (0.3, 18.1)   13.0   (1.0, 36.0)   
          Calendar year Median (IQR)  2010   (2008, 2013)   2011   (2009, 2013)   2011   (2008, 2013)   2012   (2009, 2014)   
          FEV1% Median (IQR)  69.4   (52.1, 85.6)   60.5   (42.8, 78.6)   55.3   (38.1, 74.7)   53.9   (36.6, 72.3)   
          FVC%  Median (IQR)  83.0   (68.6, 95.8)   79.9   (63.4, 92.3)   77.6   (61.2, 91.3)   74.7   (62.6, 89.6)   
          Weight (kg) Median (IQR)  57.0   (50.4, 65.3)   63.0   (55.3, 72.2)   66.1   (58.9, 75.6)   69.0   (60.5, 79.5)   
          Height (cm) Median (IQR)  166.3   (160.0, 173.1)   169.0   (162.0, 176.0)   169.0   (162.9, 175.0)   169.5   (162.0, 176.0)   
          P. aeruginosa No  1127   41.3   471   30.7   234   36.3   107   40.7   
 Yes  1599   58.7   1062   69.3   410   63.7   156   59.3   
          B. cepacia No  2621   96.1   1445   94.3   604   93.8   253   96.2   
   Yes  105   3.9   88   5.7   40   6.2   10   3.8   
          S. aureus No  1580   58.0   940   61.3   410   63.7   167   63.5   
    Yes  1146   42.0   593   38.7   234   36.3   96   36.5   
          MRSA No  2651   97.2   1480   96.5   628   97.5   255   97.0   
   Yes  75   2.8   53   3.5   16   2.5    8   3.0   
          Pancreatic insufficiency No  224   8.2   189   12.3   150   23.3   87   33.1   
 Yes  2502   91.8   1344   87.7   494   76.7   176   66.9   
          CF related diabetes No  1968   72.2   914   59.6   382   59.3   158   60.1   
 Yes  758   27.8   619   40.4   262   40.7   105   39.9   
          Hospitalisation (not for IVs) No  2649   97.2   1483   96.7   626   97.2   250   95.1   
 Yes  77   2.8   50   3.3   18   2.8   13   4.9   
          Number of hospital IV days 0 days  1648   60.5   958   62.5   458   71.1   187   71.1   
 1-14 days  487   17.9   274   17.9   109   16.9   37   14.1   
 15-28 days  245   9.0   125   8.2   36   5.6   19   7.2   
 29+ days  346   12.7   176   11.5   41   6.4   20   7.6   
          Number of home IV days 0 days  1852   67.9   931   60.7   425   66.0   188   71.5   
 1-14 days  340   12.5   227   14.8   85   13.2   28   10.6   
 15-28 days  229   8.4   132   8.6   50   7.8   20   7.6   
 29+ days  305   11.2   243   15.9   84   13.0   27   10.3   
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Table 4. Overall C-Indexes, Brier scores, and Brier score percentage reductionsa for 
prediction of 2-year, 5-year and 10-year survival from Models 1-6.  
 C-Index  Brier score  Brier score % reductiona 
 2-year 5-year 10-year  2-year 5-year 10-year  2-year 5-year 10-year 
            
Model 1 0.841 0.811 0.771  0.038 0.082 0.147  9.56 15.54 11.67 
Model 2 0.873 0.843 0.804  0.036 0.076 0.133  14.85 21.79 20.58 
Model 3 0.872 0.843 0.803  0.036 0.076 0.132  14.798 22.32 21.14 
Model 4b 0.837 0.837 0.797  0.043 0.088 0.168  -2.29 9.85 -0.70 
Model 4c 0.873 0.843 0.804  0.036 0.076 0.133  14.68 21.61 20.09 
Model 5  0.849 0.813 0.766  0.039 0.087 0.158  7.53 11.00 5.57 
Model 6 0.873 0.844 0.805  0.036 0.076 0.132  14.73 21.84 20.91 
Model 1: separate landmark models 
Model 2: supermodel with common 𝛽 coefficients across landmarks and separate baseline hazard for each landmark age 
Model 3: supermodel with interactions between each covariate and , 𝑙 and separate baseline hazard for each landmark age 
Model 4: supermodel with time-varying 𝛽 coefficients and separate baseline hazard for each landmark age 
Model 5: supermodel with common 𝛽 coefficients across landmarks, overall baseline hazard, and landmark effects  
Model 6: as in Model 2, with the addition of mixed model terms to the predictors.  
a Percentage reduction in the Brier score relative to the Brier score obtained from Kaplan-Meier estimates of survival 
probabilities (fitted separately from each landmark age with no predictors).  
b Including time-varying coefficients for all variables. 
c Including time-varying coefficients for FEV1% only. 
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Table 5. Results from fitting the final selected model to the complete data. HR: hazard ratio. 
CI: confidence interval. The confidence intervals and p-values were obtained using robust 
standard errors.  
Variable  HR 95% CI P-value 
     
Sex Male 1 (ref)   
 Female  0.87   (0.72,1.06)   0.16   
     
Genotype 2 copies 1 (ref)   
 1 copy  0.98   (0.83,1.15)   0.78   
 Other  1.05   (0.78,1.43)   0.74   
     
Age of diagnosis     0.99   (0.98,1.00)   0.17   
Calendar year     0.97   (0.95,1.00)   0.03   
FEV1%   0.97   (0.96,0.97)   <0.001   
FVC%   0.99   (0.98,1.00)   <0.001   
Weight (kg)   0.98   (0.97,0.99)   <0.001   
Height (cm)   0.99   (0.98,1.00)   0.17   
P. aeruginosa No 1 (ref)   
 Yes  1.04   (0.90,1.19)   0.63   
     
B. cepacia No 1 (ref)   
 Yes  1.91   (1.51,2.40)   <0.001   
     
S. aureus No 1 (ref)   
 Yes  0.87   (0.77,0.98)   0.02   
     
MRSA No 1 (ref)   
 Yes  1.02   (0.77,1.34)   0.90   
     
Pancreatic insufficiency No 1 (ref)   
 Yes  1.07   (0.80,1.42)   0.65   
     
CF related diabetes No 1 (ref)   
 Yes  1.48   (1.29,1.70)   <0.001   
     
Hospitalisation (not for IVs) No 1 (ref)   
 Yes  1.06   (0.79,1.41)   0.71   
     
Number of hospital IV days 0 days 1 (ref)   
 1-14 days  1.13   (0.99,1.28)   0.07   
 15-28 days  1.52   (1.31,1.76)   <0.001   
 29+ days  2.37   (2.05,2.74)   <0.001   
     
Number of home IV days 0 days 1 (ref)   
 1-14 days  1.03   (0.90,1.19)   0.66   
 15-28 days  1.06   (0.90,1.26)   0.47   
 29+ days  1.39   (1.20,1.61)   <0.001   
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Figure 1. Overview of number of individuals in each landmark data set. On the left: Number 
of individuals alive at each landmark age at any point during the study period. On the right: 
Number of deaths within 2-, 5- and 10-years after each landmark age, among those alive at 
each landmark age. 
  
  
 
Figure 2. Calibration plots using the final model (Model 2) for prediction of 2-year, 5-year 
and 10-year survival from landmark ages 20, 30, 40 and 50. The vertical axis shows the mean 
model-based x-year survival probability (x=2,5,10) in quintiles of the model-based 
probabilities. The horizontal axis shows the mean x-year survival probability obtained using 
Kaplan-Meier estimates in quintiles of the model-based probabilities. The five points have 
been joined by a line. [This plot is shown in colour in Supplementary Figure 5]. 
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Figure 3. Predicted survival curves from landmark age 30 for example individuals in groups 
defined by 5-year survival probabilities. For individuals in the Registry at age 30 between 
2013 and 2015 we obtained their predicted 5-year survival probabilities and categorized into 
groups with 5-year survival probabilities <0.5, (0.5,0.7,], (0.7,0.8], (0.8,0.9], (0.9,0.95], 
(0.95,0.99], (0.99, 1]. An example individual was created for each group. Corresponding 
results for landmark ages 20, 40 and 50 are shown in Supplementary Figure 4 
(i) Characteristics of example individualsa in groups defined by 5-year survival probability.  
5-year survival probability group <0.5 (0.5,0.7] (0.7,0.8] (0.8,0.9] (0.9,0.95] (0.95,0.99] (0.99,1] 
Example person 1 2 3 4 5 6 7 
Males/Femalesb        
Genotype (no. copies of F508del) 2 2 2 2 2 2 1 
Age of diagnosis (years)  0, 0    0, 0    0, 1    0, 1    0, 0    0, 1    5, 3   
FEV1%  29, 25    24, 38    35, 32    36, 43    51, 54    71, 76    91, 97     
FVC%  31, 36    49, 57    57, 50    63, 61    69, 70    88, 89    100, 102     
Weight (kg)  48, 48    64, 47    60, 52    62, 55    69, 56    70, 58    77, 68     
Height (cm)  170, 156    172, 156    173, 156    172, 162  173, 163    174, 162    178, 166     
P. aeruginosa No, Yes Yes Yes Yes Yes Yes Yes 
B. cepacia Yes, No No No No No No No 
S. aureus No No No No No No No, Yes 
MRSA No No No No No No No 
Pancreatic insufficiency Yes Yes Yes Yes Yes Yes Yes 
CF related diabetes Yes Yes Yes Yes Yes No No 
Hospitalisation (not for IVs) No No No No No No No 
Number of hospital IV days 29+  29+  29+, 0 0  0  0  0  
Number of hospital IV days 0, 29+ 0, 29+ 0, 29+ 0 0 0 0 
aWe created an example individual for each group using the median values of the continuous predictors and the most 
common value of each categorical variable within that group. This was done separately for males and females. 
b Values are shown as ‘male, female’, except were the value for males and females was the same. 
(ii) Predicted survivor curves based on the final model for example individuals with characteristics shown in the table above. 
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Figure 4. Plots showing the distribution of 2-, 5- and 10-year survival probabilities from 
landmark ages 20, 30, 40 and 50 for individuals in the Registry at those ages between 2013 
and 2015. [This plot is shown in colour in Supplementary Figure 6]. 
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Supplementary materials for: 
Dynamic prediction of survival in cystic fibrosis:  
A landmarking analysis using UK patient registry data 
 
S1. Creation of landmark data sets 
Supplementary Figure 1 illustrates how the landmark data sets arose. An individual was included in the 
landmark data set at age 𝑙 if they met all of the following criteria: 
 They reached age 𝑙 between 1st January 2005 and 31st December 2015. 
 They joined the Registry prior to reaching age 𝑙. The date of joining the Registry is the date of 
the first annual review at which data were obtained. 
 They were diagnosed with CF prior to reaching age 𝑙. 
 They have not received an organ transplant of any type prior to reaching age 𝑙. 
 They have measures of all time-dependent variables recorded prior to reaching age 𝑙.  
 
We refer to an individual as “eligible for the 𝑙th landmark data set” if she/he satisfied these five 
conditions. Supplementary Table 1 summarises the landmark data sets in terms of number of 
individuals, number of deaths within 2, 5 and 10 years of the landmark age, and number of censorings.  
 
S2. Survival prediction models 
Time scale and follow-up 
In all models the time origin is date of birth and analyses are performed using left-truncation at the 
landmark age. The censoring time was the earliest of death, 31st December 2015 and a specified time 
horizon 𝑡ℎ𝑜𝑟. Since dates of birth and death were only available in month/year format, the day was 
imputed as the 15th of the month. For example, an individual aged 18 on 1st January 2005 (who has been 
diagnosed, joined the Registry, and not received a transplant) contributes up to 11 years of follow-up 
until the end of 2015 to the landmark data set for age 18 and up to 10 years of follow-up for the landmark 
dataset for age 19 (if they do not die, become lost-to-follow-up, or have a transplant between ages 18 
and 19), and so on. An individual aged 18 on 1st January 2014 contributes up to 2 years of follow-up to 
the landmark data set for age 18 and up to 1 year of follow-up for the landmark dataset for age 19.  
 
The UK CF Registry aims to capture deaths from all causes. Of the 931 deaths used in this study, 775 
(83.2%) were due to respiratory or cardiorespiratory failure, 55 (5.9%) were transplantation-related, 13  
(1.4%) were due to liver disease or failure, 9 (1.0%) were due to cancer, 9 (1.0%) were due to trauma 
or suicide, 34 (3.7%) were due to “other causes” (recorded in a separate field and including “End state 
cystic fibrosis” and “Haemoptysis”), 35 (3.9%) were due to an unknown cause, and for 1 individual the 
cause was not recorded. 
 
We assumed that all deaths are captured and the main results presented assume censoring is entirely 
administrative. In a sensitivity analysis we treated individuals not recorded at an annual follow-up for 
over 2 years as lost-to-follow-up. This did not materially alter the results – the C-indexes for 2-5- and 
10-year survival from the final model (Model 2) were 0.874, 0.847, 0.807 respectively, and 
corresponding Brier scores were 0.036, 0.075, 0.130.  
 
Landmark survival models 
 
We let 𝑍 denote the vector of baseline predictors (sex, genotype and age of diagnosis) and 𝑋(𝑙) denote 
the vector of the last-observation-carried-forward (LOCF) values for time-dependent predictors 
(calendar year, FEV%, FEV%, weight, height, CFRD. pancreatic insufficiency, Pseudomonas 
aeruginosa, Burkholderia cepacia, Staphylococcus aureus, Methicillin-resistant Staphylococcus 
aureus (MRSA), non-IV hospitalization, number of IV days) at landmark age 𝑙. 
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Model 1 for the log conditional hazard is 
 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0𝑙(𝑡) + 𝛽𝑙
𝑇𝑋(𝑙) + 𝛾𝑙
𝑇𝑍, 𝑙 = 1, … , 𝐿              Model 1 
 
where ℎ0𝑙(𝑡) is the baseline hazard at age 𝑡 conditional on eligibility for the 𝑙th landmark data set, and 
𝛽𝑙 and 𝛾𝑙 are vectors of log hazard ratios specific to landmark age 𝑙. Model 1 is in fact 𝐿 models, which 
are fitted in each landmark data set 𝑙 = 1, … , 𝐿.  
 
Model 2 for the log conditional hazard is 
 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0𝑙(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍          Model 2 
 
where ℎ0𝑙(𝑡) is again the baseline hazard at age 𝑡 conditional on eligibility for the 𝑙th landmark data set 
(𝑙 = 1, … , 𝐿). 𝛽 and 𝛾 are vectors of log hazard ratios, which are assumed to be the same for all 𝑙. Model 
2 therefore allows a separate baseline hazard from each landmark age, but common predictor 
coefficients across all landmark ages. It is fitted in the stacked data set using Cox regression with a 
stratified baseline hazard.1,2 We note that for Models 1 and 2, using age as the time scale or time-since-
landmark as the timescale are exactly equivalent. 
 
Models 1 and 2 make the proportional hazards assumption that the association of the predictors 𝑋(𝑙) 
and 𝑍 with the hazard is the same over time since 𝑙, i.e. that the 𝛽𝑙 and 𝛽 parameters are not time-
dependent. Models 1 and 2 were initially fitted using a time horizon of 10 years (𝑡ℎ𝑜𝑟 = 10), which 
enables us to obtain predicted survival probabilities for any time up to 10 years. We also investigated 
whether 2-year and 5-year survival could be better predicted by using a shorter time horizon by fitting 
Models 1 and 2 using 𝑡ℎ𝑜𝑟 = 2 and 𝑡ℎ𝑜𝑟 = 5 respectively.  
 
Model 3 extends Model 2 by allowing the log hazard ratios to depend on 𝑙 in a smooth way: 
 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0𝑙(𝑡) + 𝛽(𝑙)
𝑇𝑋(𝑙) + 𝛾(𝑙)𝑇𝑍          Model 3 
 
where 𝛽(𝑙) and 𝛾(𝑙) denote vectors of log hazard ratios that are functions of 𝑙. We considered linear 
forms 𝛽(𝑙) = 𝛽0 + 𝛽 × (𝑙 − 18) and 𝛾(𝑙) = 𝛾0 + 𝛾 × (𝑙 − 18) and restricted cubic spline forms with 
knots at 18, 30, 40 and 50. The results reported in Table 4 of the main text are from the analysis using 
the linear form for 𝛽(𝑙), as using restricted cubic splines did not materially improve predictive 
performance.  
 
In Model 4 the supermodel was extended to allow time-varying coefficients, with the association 
between the predictors and the hazard dependent on time-since landmark (𝑡 − 𝑙): 
 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0𝑙(𝑡) + 𝛽(𝑡 − 𝑙)
𝑇𝑋(𝑙) + 𝛾(𝑡 − 𝑙)𝑇𝑍          Model 4 
 
where 𝛽(𝑡 − 𝑙) and 𝛾(𝑡 − 𝑙) denote vectors of log hazard ratios that are functions of 𝑡 − 𝑙. We 
considered linear forms 𝛽(𝑡 − 𝑙) = 𝛽0 + 𝛽 × (𝑡 − 𝑙) and 𝛾(𝑡 − 𝑙) = 𝛾0 + 𝛾 × (𝑡 − 𝑙) and restricted 
cubic spline forms with knots at 𝑡 − 𝑙 = 2,5,8. The results reported in Table 4 of the main text are from 
the analysis using the linear form for 𝛽(𝑡 − 𝑙), as using restricted cubic splines did not materially 
improve predictive performance. 
 
Model 5 uses an overall baseline hazard instead of separate baseline hazards for each landmark age, 
with the impact of landmark age modelled using regression terms: 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍 + 𝑓(𝑙; 𝛿)         Model 5 
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where ℎ0(𝑡) is a common baseline hazard and 𝑓(𝑙; 𝛿) is a function of landmark age. We used a restricted 
cubic spline form for 𝑓(𝑙; 𝛿) with knots at 18, 30, 40 and 50.  
In Model 6 we extended Model 2 by adding the fitted values and slopes from the multivariate mixed 
model (see below) for FEV%, FVC% and weight to the set of time-dependent predictors at each 
landmark age: 
log ℎ𝑙(𝑡|𝑋(𝑙), 𝑍) = log ℎ0𝑙(𝑡) + 𝛽
𝑇𝑋(𝑙) + 𝛾𝑇𝑍 + 𝜃𝑇𝑋∗(𝑙)          Model 6 
 
where 𝑋∗(𝑙) denotes the vector of predicted values and slopes for FEV%, FVC% and weight from the 
multivariate mixed model. 
 
All models were fitted by maximum partial likelihood.  
 
Multivariate mixed model 
 
A multivariate linear mixed model for FEV1%, FVC%, BMI and weight was fitted to the repeated 
measures up to landmark age 𝑙 (𝑙 = 1, … , 𝐿) for individuals in the landmark data set at age 𝑙. Separate 
models were fitted for each landmark age. The longitudinal variables were modelled as a linear function 
of age with a random intercept and slope. We also included fixed effects of all the other predictors, 
including both baseline and time-dependent predictors. For each individual in landmark dataset 𝑙 (𝑙 =
1, … , 𝐿) the individual fitted values and slopes for FEV1%, FVC% and weight at age 𝑙 were obtained. 
The numbers of longitudinal measurements used in the multivariate mixed models are summarised in 
Supplementary Table 2. 
Predicted survival probabilities 
From each model the predicted survival probability to time 𝑡 after the landmark age, conditional on 
survival to the landmark age, on baseline variables 𝑍 and on values of time-dependent predictors at the 
landmark age 𝑋(𝑙),  𝑆(𝑙 + 𝑡|𝑋(𝑙), 𝑍, 𝑇 > 𝑙), was obtained using the relationship 
𝑆(𝑙 + 𝑡|𝑋(𝑙), 𝑍, 𝑇 > 𝑙) = exp {− ∫ ℎ(𝑢|𝑋(𝑙), 𝑍, 𝑢 > 𝑙)
𝑙+𝑡
𝑙
𝑑𝑢} 
For models without time-varying hazard ratios (Models 1-3 and 5-6) we used the estimator: 
?̂?(𝑙 + 𝑡|𝑋(𝑙), 𝑍, 𝑇 > 𝑙) = exp {−𝑒?̂?
𝑇𝑋(𝑙)+?̂?𝑇𝑍 ∑ ℎ̂0𝑢
𝑙<𝑢≤𝑙+𝑡
} 
where ℎ̂0𝑢 denotes the baseline hazard at time 𝑢 estimated from the increments in Breslow’s estimate 
of the cumulative baseline hazard  and the sum is over event times.3 For Model 4, which has time-
varying hazard ratios, we used the estimator 
?̂?(𝑙 + 𝑡|𝑋(𝑙), 𝑍, 𝑇 > 𝑙) = exp {− ∑ ℎ̂0𝑢𝑒
?̂?𝑇(𝑢−𝑙)𝑋(𝑙)+?̂?𝑇(𝑢−1)𝑍
𝑙<𝑢≤𝑙+𝑡
} 
S3. Model assessment 
 
Overview 
 
Models were assessed and compared based on the “3-in-1” procedure described by Yong et al (2013), 
which incorporates model building using cross-validation, final model choice, and statistical inference.4 
The data were first divided into a “training+validation” (TV) set and a “holdout” set. The TV set is used 
in the model development and assessment. The holdout set is reserved for applying the selected model 
at the end. No models are fitted using the holdout data. The TV set is a sample of 80% from the stacked 
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data, stratified by landmark age. The holdout set is formed from the remaining 20% of individuals at 
each landmark age. Some individuals appear in both the TV and holdout stacked data sets, but not with 
the same landmark age. 
For model assessment we used the C-index,5–8 the Brier score,9,10 and percentage reduction in the Brier 
score relative to the null model (i.e. the model excluding all predictors, using Kaplan-Meier estimates).11 
The C-index and Brier scores were obtained using inverse probability of censoring weights. For Model 
4 we accommodated the time-varying coefficients into the estimation of the C-Index and Brier score.8 
A Monte-Carlo cross-validation procedure was used within the TV data set to avoid over-optimism due 
to overfitting 12. The procedure was as follows: 
(i) An 80% stratified random sample, with stratification by landmark age 𝑙, was obtained from the TV 
data set. 
(ii) The model was fitted on the 80% sample. 
(iii) The fitted model was used to obtain predicted survival probabilities to a given time from each 
landmark age 𝑙 (see below) for the 20% not in the sample. 
(iv) Model performance measures (C-index, Brier score, and percentage reduction in the Brier score) 
were obtained in the 20% not in the sample on which the model was fitted. 
(v) Steps (i)-(iv) were repeated 200 times and we obtained the average C-index, Brier score and Brier 
score reduction across the 200 samples.  
Model assessment measures were obtained for 2-year, 5-year and 10-year survival from each landmark 
age. Therefore there are 99 averaged C-indices and Brier scores for each model (33 × 3, where 33 is 
the number of landmark ages 18-50). For each model we also obtained an overall C-index and Brier 
score which are not age-adjusted. Further details are given below. To simplify the notation we give the 
details of the C-index and Brier score as if applied to the complete stacked data (the TV and holdout 
data combined). 
 
Truncated C-Index 
The following description of the C-index follows that of Gerds et al..7 Let 𝑇𝑖 and 𝐶𝑖 denote respectively 
the event time and censoring time for individual 𝑖. We observe ?̃?𝑖 = min(𝑇𝑖 , 𝐶𝑖) and the event indicator 
Δ𝑖 = 1(𝑇𝑖 < 𝐶𝑖). Let ?̂?𝑙(𝑙 + 𝑡|𝑋(𝑙), 𝑍) denote the estimated probability of survival beyond age 𝑙 +
𝑡 conditional on survival to age 𝑙 and given predictor values 𝑋(𝑙), 𝑍 at age 𝑙. The truncated C-index is 
𝐶𝑙(𝑡) = 𝐸𝑖𝑗{1{?̂?𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍𝑖) < ?̂?𝑙(𝑙 + 𝑡|𝑋𝑗(𝑙), 𝑍𝑖)}|𝑇𝑖 < 𝑇𝑗, 𝑇𝑖 ≤ 𝑙 + 𝑡, 𝑇𝑖 > 𝑙, 𝑇𝑗 > 𝑙}              
where the expectation is with respect to two subjects 𝑖, 𝑗, both alive at age 𝑙 (𝑇𝑖 > 𝑙). Not all pairs of 
individuals 𝑖, 𝑗 are comparable. We can compare two individuals who both have the event prior to age 
𝑙 + 𝑡; two individuals, one of whom has the event prior to age 𝑙 + 𝑡 and the other of which is known to 
be alive (censored) at age 𝑙 + 𝑡. We cannot compare two individuals who are both known to be alive 
(censored) at age 𝑙 + 𝑡, two individuals both censored before age 𝑙 + 𝑡, or a pair in which one individual 
has the event and the other is censored before the other’s event time. The fact that not all pairs of 
individuals can be compared is handled using inverse probability of censoring weights (IPCW). The 
truncated C-Index can be expressed as 
𝐶𝑙(𝑡)
=
𝐸𝑖𝑗{1{?̂?𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍) < ?̂?𝑙(𝑙 + 𝑡|𝑋𝑗(𝑙), 𝑍𝑗)}|𝑇𝑖 > 𝑙, 𝑇𝑗 > 𝑙}𝐸𝑖𝑗{𝑇𝑖 < 𝑇𝑗, 𝑇𝑖 ≤ 𝑙 + 𝑡|𝑇𝑖 > 𝑙, 𝑇𝑗 > 𝑙, 𝑋𝑖(𝑙), 𝑋𝑗(𝑙)}
Pr(𝑇𝑖 < 𝑇𝑗, 𝑇𝑖 ≤ 𝑙 + 𝑡|𝑇𝑖 > 𝑙, 𝑇𝑗 > 𝑙)
=
𝐸𝑖𝑗 {1{?̂?𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍𝑖) < ?̂?𝑙(𝑙 + 𝑡|𝑋𝑗(𝑙), 𝑍𝑖)} ∫ 𝑆(𝑢|𝑋𝑗(𝑙), 𝑍𝑖 , 𝑢 > 𝑙)
𝑙+𝑡
𝑙
𝑆(𝑑𝑢|𝑋𝑖(𝑙), 𝑍, 𝑢 > 𝑙)|𝑇𝑖 > 𝑙, 𝑇𝑗 > 𝑙}
𝐸𝑖𝑗 {∫ 𝑆(𝑢|𝑋𝑗(𝑙), 𝑍, 𝑢 > 𝑙)
𝑙+𝑡
𝑙
𝑆(𝑢|𝑋𝑖(𝑙), 𝑍, 𝑢 > 𝑙)}
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We assume that the event and censoring time are independent conditional on the variables, i.e. 
𝐶𝑖 ∐ 𝑇𝑖|𝑋𝑖(𝑙), 𝑇𝑖 > 𝑙, 𝐶𝑖 > 𝑙, and that the probability of being uncensored at the prediction horizon 𝑙 + 𝑡 
is bounded away from 0.  This gives rise to the IPCW estimator 
?̂?𝑙(𝑡)
=
∑ ∑ 1{?̂?𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍) < ?̂?𝑙(𝑙 + 𝑡|𝑋𝑗(𝑙), 𝑍)}1{?̃?𝑖 < ?̃?𝑗}
𝑛𝑙
𝑗=1
𝑛𝑙
𝑖=1 1{?̃?𝑖 ≤ 𝑙 + 𝑡, Δi = 1}?̂?𝑖𝑗
−1
∑ ∑ 1{?̃?𝑖 < ?̃?𝑗}
𝑛𝑙
𝑗=1
𝑛𝑙
𝑖=1 1{?̃?𝑖 ≤ 𝑙 + 𝑡, Δi = 1}?̂?𝑖𝑗
−1
         
of 𝐶𝑙(𝑡), where  ?̂?𝑖𝑗 = Pr̂(𝐶𝑗 > ?̃?𝑖|𝑋𝑗(𝑙), 𝑍, ?̃?𝑗 > 𝑙) Pr̂(𝐶𝑖 ≥ ?̃?𝑖|𝑋𝑖(𝑙), 𝑍, ?̃?𝑖 > 𝑙) is a weight, where the 
censoring probabilities used in the weight are obtained from a model to be specified (see below).  
The C-index 𝐶𝑙(𝑡) is conditional on survival to age 𝑙 and a separate estimated C-index is obtained for 
any combination of 𝑙 and 𝑡 (𝑙 = 18, … ,50; 𝑡 = 2,5,10). We also considered an overall C-index which 
is combined across landmark ages. Consider the stacked landmark data set and let 𝐿𝑖 denote the 
landmark age for record (row) 𝑖. Some individuals appear in more than one row in the stacked landmark 
data set and we define 𝐼𝐷(𝑖) to be the unique identifier (ID number) for the individual in  row 𝑖. The 
overall C-index is 
𝐶overall(𝑡) = 𝐸𝑖𝑗 {1(𝐼𝐷(𝑖) ≠ 𝐼𝐷(𝑗))1 {?̂?𝐿𝑖(𝐿𝑖 + 𝑡|𝑋𝑖(𝑙), 𝑍) < ?̂?𝐿𝑗(𝐿𝑗 + 𝑡|𝑋𝑗(𝑙), 𝑍)} |(𝑇𝑖 − 𝐿𝑖)
< (𝑇𝑗 − 𝐿𝑖), (𝑇𝑖 − 𝐿𝑖) ≤ 𝑡} 
where the expectation is with respect to two rows 𝑖, 𝑗 in the stacked landmark data set. Inclusion of the 
indicator 1(𝐼𝐷(𝑖) ≠ 𝐼𝐷(𝑗)) ensures that an individual is not compared with herself/himself. An 
estimator incorporating censoring weights is  
?̂?overall(𝑡)
=
∑ ∑ 1 {?̂?𝐿𝑖(𝐿𝑖 + 𝑡|𝑋𝑖(𝑙), 𝑍) < ?̂?𝐿𝑗(𝐿𝑗 + 𝑡|𝑋𝑗(𝑙), 𝑍)} 1{(?̃?𝑖 − 𝐿𝑖) < (?̃?𝑗 − 𝐿𝑖)}
𝑁
𝑗=1
𝑁
𝑖=1 1{?̃?𝑖 − 𝐿𝑖 ≤ 𝑡, Δi = 1}?̂?𝑖𝑗
∗−1
∑ ∑ 1{(?̃?𝑖 − 𝐿𝑖) < (?̃?𝑗 − 𝐿𝑗}
𝑁
𝑗=1
𝑁
𝑖=1 1{(?̃?𝑖 − 𝐿𝑖) ≤ 𝑡, Δi = 1}?̂?𝑖𝑗
∗−1
     
where 𝑁 is the total number of individuals in the stacked landmark data set and the weights are 
?̂?𝑖𝑗
∗ = Pr̂((𝐶𝑗 − 𝐿𝑗) > (?̃?𝑖 − 𝐿𝑖)|𝑋𝑗(𝐿𝑗), ?̃?𝑗 > 𝐿𝑗) Pr̂((𝐶𝑖 − 𝐿𝑖) ≥ (?̃?𝑖 − 𝐿𝑖)|𝑋𝑖(𝐿𝑖), ?̃?𝑖 > 𝐿𝑖). 
We assumed that the probabilities in the weights ?̂?𝑖𝑗 do not depend on 𝑋𝑗(𝑙)  or 𝑍 and therefore used 
Pr̂(𝐶𝑗 > ?̃?𝑖|?̃?𝑗 > 𝑙) in place of s Pr̂(𝐶𝑗 > ?̃?𝑖|𝑋𝑗(𝑙), ?̃?𝑗 > 𝑙) and Pr̂(𝐶𝑖 ≥ ?̃?𝑖|?̃?𝑖 > 𝑙)  in place of Pr̂ (𝐶𝑖 ≥
?̃?𝑖|𝑋𝑖(𝑙), 𝑍, ?̃?𝑖 > 𝑙). The probabilities were estimated separately from each landmark age using Kaplan-
Meier estimates. A similar approach was used for the weights ?̂?𝑖𝑗
∗ .   
In summary we obtained ?̂?overall(𝑡) for 𝑡 = 2,5,10 and ?̂?𝑙(𝑡) for 𝑡 = 2,5,10 and 𝑙 = 18, … ,50. 
Brier score 
The Brier score is the mean squared prediction error. As for the C-index, we obtained separate Brier 
scores at each landmark age and an overall brier score.  In the absence of censoring an estimator of the 
Brier score is  
?̂?𝑙(𝑡) =
1
𝑛𝑙
∑ {?̂?𝑖𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍𝑖) − 𝐼𝑖(𝑇𝑖 > 𝑙 + 𝑡|𝑇𝑖 > 𝑙)}
2
𝑖∈𝐷𝑙
 
where ?̂?𝑖𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍𝑖) is the model-based estimated probability of survival to age 𝑙 + 𝑡 for individual 
𝑖 in the landmark data set at age 𝑙, 𝐼𝑖(𝑡 > 𝑙 + 𝑡|𝑇𝑖 > 𝑙) is the observed indicator of survival to age 𝑙 + 𝑡, 
and the sum is over the 𝑛𝑙 individuals in landmark data set 𝑙 (𝐷𝑙). An estimator incorporating inverse 
probability of censoring weights is 
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?̂?𝑙(𝑡) =
1
𝑛𝑙
∑ 𝐼(𝑑𝑖 = 1 ∪ 𝑇𝑖 > 𝑙 + 𝑡){?̂?𝑖𝑙(𝑙 + 𝑡|𝑋𝑖(𝑙), 𝑍𝑖) − 𝐼𝑖(𝑇𝑖 > 𝑙 + 𝑡|?̃?𝑖 > 𝑙)}
2
𝑖∈𝐷𝑙
?̂?𝑖
−1 
where 𝑑𝑖 is the event indicator, 𝐼(𝑑𝑖 = 1 ∪ 𝑇𝑖 > 𝑙 + 𝑡) is an indicator taking value 1 for individuals 
who have the event or whose censoring age is after 𝑡 + 𝑙, and zero otherwise, and ?̂?𝑖 =
Pr̂(𝐶𝑖 > min (𝑇𝑖
−, 𝑙 + 𝑡)|?̃?𝑖 > 𝑙) is the probability of being censored beyond age min (𝑇𝑖
−, 𝑙 + 𝑡). The 
inverse probability of censoring weights were obtained using Kaplan-Meier estimates stratified by 
landmark age. 
The overall Brier score estimator is  
?̂?overall(𝑡) =
1
𝑁
∑ 𝐼(𝑑𝑖 = 1 ∪ 𝑇𝑖 > 𝐿𝑖 + 𝑡){?̂?𝑖𝐿𝑖(𝐿𝑖 + 𝑡|𝑋𝑖(𝐿𝑖), 𝑍𝑖) − 𝐼𝑖(𝑇𝑖 > 𝐿𝑖 + 𝑡|?̃?𝑖 > 𝑙)}
2
𝑖
?̂?𝑖
−1 
where the sum is over all rows in the stacked landmark data set and ?̂?𝑖 = Pr̂(𝐶𝑖 > min (𝑇𝑖
−, 𝐿𝑖 +
𝑡)|?̃?𝑖 > 𝐿𝑖).  
Brier scores were also obtained under a null model using Kaplan-Meier estimates of the survival 
probabilities stratified by landmark age but with no other predictors. These are denoted ?̂?𝑙,null(𝑡) and 
?̂?overall,null(𝑡). The percentage reduction in the Brier score from a given model compared with the null 
model was calculated using 100(?̂?𝑙,null(𝑡) − ?̂?𝑙(𝑡))/ ?̂?𝑙,null(𝑡) and 100(?̂?overall,null(𝑡) − ?̂?overall(𝑡))/
 ?̂?𝑜verall,null(𝑡).  
In summary we obtained ?̂?overall(𝑡) for 𝑡 = 2,5,10 and ?̂?𝑙(𝑡) for 𝑡 = 2,5,10 and 𝑙 = 18, … ,50, and the 
corresponding percentages reductions in the Brier score relative to the null model.  
Calibration plots 
After selecting the final model, calibration plots were obtained to show graphically the agreement 
between predicted survival probabilities from the model and the ‘true’ probabilities. The steps for 
creating these plots were as follows: 
Steps (i)-(iii) are the same as described earlier, in the Overview section of S3.  
(iv) The predicted 2-year survival probabilities from landmark age 𝑙 were divided into quintiles and we 
obtained the mean predicted 2-year survival probability for individuals within each quintile, denoted 
𝑆̅(2)𝑙,𝑄1, 𝑆̅(2)𝑙,𝑄2, 𝑆̅(2)𝑙,𝑄3, 𝑆̅(2)𝑙,𝑄4, 𝑆̅(2)𝑙,𝑄5. We also obtained the Kaplan-Meier estimate of 2-year 
survival for the individuals within each quintile, denoted 
𝐾𝑀(2)𝑙,𝑄1, 𝐾𝑀(2)𝑙,𝑄2, 𝐾𝑀(2)𝑙,𝑄3, 𝐾𝑀(2)𝑙,𝑄4, 𝐾𝑀(2)𝑙,𝑄5. The same was done for 5-year and 10-year 
survival. 
(v) Steps (i)-(iv) were repeated 200 times and for each 𝑙 = 18, … ,50 we obtained the average of each 
𝑆̅(2)𝑙,𝑄1, … , 𝑆̅(2)𝑙,𝑄5 and the average of each 𝐾𝑀(2)𝑙,𝑄1, 𝐾 … , 𝐾𝑀(2)𝑙,𝑄5 across the 200 samples..  
(vi) The averaged 𝑆̅(2)𝑙,𝑄1, … , 𝑆̅(2)𝑙,𝑄5 from step (v) were plotted against the averaged 
𝐾𝑀(2)𝑙,𝑄1, 𝐾 … , 𝐾𝑀(2)𝑙,𝑄5.  
 
Calibration plots for landmark ages 20,30,40 and 50 are shown in the main text Figure 2. In a well-
calibrated model the five points lie on the 𝑦 = 𝑥 line.  
 
S4. Software 
All analyses were performed using R. The landmark models described in Section S2 can be fitted easily 
using the coxph function from the survival package  after some rearrangement of the data.13 Some of 
the data rearrangement can be performed using the dynpred package,14 for example using the cutLM 
function, though we did not use that here. Estimated survival probabilities can be obtained using 
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‘predict’ after coxph, though special code was written to obtain the predicted survival probabilities from 
Model 4, which included time-varying coefficients.  
There exist various packages for obtaining C-indexes and Brier scores. None of the existing functions 
for estimating the C-index appear to accommodate a stratified baseline hazard, and so we used bespoke 
code. We used ‘pew’ from the dynpred package to estimate the Brier scores; this requires pre-estimation 
of matrices of predicted survival and censoring probabilities.  
The multivariate mixed model used to obtain the additional predictors 𝑋∗(𝑙) for Model 6 was fitted 
using the lme function from the nlme package.15 Existing software, including the nlme package, does 
not appear to allow out-of-sample predictions from mixed models. We therefore used bespoke code 
which is available from https://github.com/ruthkeogh/landmark_CF. 
S5. Final model specification 
Example code for obtaining estimated survival probabilities from the final model is provided at 
https://github.com/ruthkeogh/landmark_CF. This includes csv files containing estimated cumulative 
baseline hazards for each landmark age (𝑙 = 18, … ,50). 
S6. Comparisons with other models 
In an analysis of the French CF Registry Nkam et al reported a cross-validated C-statistic of 0.90 for 
prediction of 3-year survival.16 They did not report a Brier score. Aside from focusing on 3-year 
survival and using different set of predictors, there are a number of differences between their 
approach and ours. They used a composite outcome of death and transplant, and for their logistic 
regression analysis, they excluded individuals who were censored before the end of the 3-year follow-
up period.  
Liou et al used a logistic regression analysis of the US CF Registry to predict 5-year survival.17 A 
calibration plot showed good performance using a validation data set. However, they did not present 
measures of predictive performance that are comparable to those in this paper. Mayer-Hamblett et al 
also used a logistic regression analysis of the US CF Registry to develop a model for predicting 2-year 
survival.18 They presented an ROC curve but did not report an area under the ROC curve, which could 
be compared to our C-Index. They presented sensitivities and specificities, and positive- and negative 
predictive values, finding that their model was better at predicting who would survive 2 years than 
who would die.  
McCarthy et al developed the CF-ABLE score using logistic regression modelling of data from the CF 
population in Ireland.19 Based on a validation data set, the area under the ROC curve was 0.82 for 4-
year survival, though it is not clear how censoring was treated. 
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Supplementary Figure 1. Summary of data exclusions and creation of data set for analysis.  
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Supplementary Table 1. Summary of number of individuals, deaths, censorings and total person time at risk in each landmark 
data set. The stacked data set is formed by combining the landmark data sets.  
  Number of deaths: N (%) Number of censorings: N (%) 
Landmark  
age 
No. 
of 
individuals 
Within 
2 years 
Within 
5 years 
Within 
10 years 
Within 
2 years 
Within 
5 years 
Within 
10 years 
 18   2725   63 (2.3)   171 (6.3)   255 (9.4)   500 (18.3)   1243 (45.6)   2290 (84.0)  
  19   2756   86 (3.1)   206 (7.5)   290 (10.5)   522 (18.9)   1244 (45.1)   2294 (83.2)  
  20   2726   104 (3.8)   218 (8.0)   303 (11.1)   505 (18.5)   1215 (44.6)   2239 (82.1)  
  21   2622   96 (3.7)   209 (8.0)   291 (11.1)   497 (19.0)   1221 (46.6)   2185 (83.3)  
  22   2526   107 (4.2)   206 (8.2)   273 (10.8)   477 (18.9)   1194 (47.3)   2104 (83.3)  
  23   2431   99 (4.1)   196 (8.1)   258 (10.6)   463 (19.0)   1159 (47.7)   2022 (83.2)  
  24   2326   85 (3.7)   182 (7.8)   234 (10.1)   501 (21.5)   1136 (48.8)   1970 (84.7)  
  25   2225   80 (3.6)   167 (7.5)   219 (9.8)   486 (21.8)   1088 (48.9)   1878 (84.4)  
  26   2079   82 (3.9)   160 (7.7)   216 (10.4)   439 (21.1)   1026 (49.4)   1760 (84.7)  
  27   1953   81 (4.1)   153 (7.8)   205 (10.5)   412 (21.1)   960 (49.2)   1647 (84.3)  
  28   1801   74 (4.1)   145 (8.1)   189 (10.5)   386 (21.4)   909 (50.5)   1540 (85.5)  
  29   1675   59 (3.5)   117 (7.0)   164 (9.8)   385 (23.0)   882 (52.7)   1436 (85.7)  
  30   1533   61 (4.0)   112 (7.3)   149 (9.7)   355 (23.2)   822 (53.6)   1323 (86.3)  
  31   1396   52 (3.7)   102 (7.3)   135 (9.7)   330 (23.6)   772 (55.3)   1205 (86.3)  
  32   1286   49 (3.8)   110 (8.6)   132 (10.3)   338 (26.3)   721 (56.1)   1112 (86.5)  
  33   1185   44 (3.7)   99 (8.4)   124 (10.5)   316 (26.7)   671 (56.6)   1011 (85.3)  
  34   1062   46 (4.3)   92 (8.7)   114 (10.7)   283 (26.6)   588 (55.4)   899 (84.7)  
  35   981   45 (4.6)   84 (8.6)   104 (10.6)   253 (25.8)   533 (54.3)   807 (82.3)  
  36   881   43 (4.9)   74 (8.4)   94 (10.7)   228 (25.9)   473 (53.7)   750 (85.1)  
  37   796   32 (4.0)   60 (7.5)   83 (10.4)   200 (25.1)   425 (53.4)   685 (86.1)  
  38   732   31 (4.2)   56 (7.7)   74 (10.1)   181 (24.7)   373 (51.0)   623 (85.1)  
  39   688   27 (3.9)   56 (8.1)   72 (10.5)   163 (23.7)   346 (50.3)   581 (84.4)  
  40   644   19 (3.0)   47 (7.3)   68 (10.6)   141 (21.9)   319 (49.5)   544 (84.5)  
  41   618   20 (3.2)   48 (7.8)   71 (11.5)   124 (20.1)   327 (52.9)   518 (83.8)  
  42   606   30 (5.0)   50 (8.3)   72 (11.9)   131 (21.6)   314 (51.8)   501 (82.7)  
  43   579   24 (4.1)   57 (9.8)   72 (12.4)   130 (22.5)   302 (52.2)   485 (83.8)  
  44   530   19 (3.6)   45 (8.5)   64 (12.1)   141 (26.6)   277 (52.3)   447 (84.3)  
  45   497   20 (4.0)   47 (9.5)   65 (13.1)   131 (26.4)   274 (55.1)   415 (83.5)  
  46   425   23 (5.4)   42 (9.9)   57 (13.4)   96 (22.6)   229 (53.9)   353 (83.1)  
  47   391   23 (5.9)   42 (10.7)   54 (13.8)   93 (23.8)   215 (55.0)   327 (83.6)  
  48   347   14 (4.0)   35 (10.1)   45 (13.0)   98 (28.2)   202 (58.2)   292 (84.1)  
  49   307   15 (4.9)   34 (11.1)   39 (12.7)   92 (30.0)   184 (59.9)   260 (84.7)  
  50   263   17 (6.5)   31 (11.8)   37 (14.1)   71 (27.0)   154 (58.6)   218 (82.9)  
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Supplementary Table 2. Summary of number of measurements of FEV1%, FVC% and weight used in multivariate mixed 
models fitted up to each landmark age. Results shown are the median, interquartile range (IAQR) and range of the number of 
measurements of each variable up to age 𝑙 for individuals in the 𝑙th landmark data set (𝑙 = 18, … ,50). 
 FEV1% FVC1% Weight 
Landmark 
age 
Median IQR Range Median IQR Range Median IQR Range 
18 7 (5,10) (1,20) 7 (5,10) (1,20) 8 (5,11) (1,21) 
19 7 (5,10) (1,21) 7 (5,10) (1,21) 8 (5,11) (1,22) 
20 7 (5,10) (1,22) 7 (5,10) (1,22) 8 (5,11) (1,22) 
21 7 (5,10) (1,21) 7 (5,10) (1,21) 8 (5,11) (1,21) 
22 8 (5,10) (1,21) 8 (5,10) (1,21) 8 (5,11) (1,21) 
23 8 (5,10) (1,22) 8 (5,10) (1,22) 8 (5,11) (1,22) 
24 8 (5,11) (1,24) 8 (5,11) (1,24) 8 (6,11) (1,24) 
25 8 (6,11) (1,24) 8 (5,11) (1,24) 8 (6,11) (1,24) 
26 8 (5,11) (1,24) 8 (5,11) (1,24) 8 (6,11) (1,25) 
27 8 (5,11) (1,23) 8 (5,11) (1,23) 8 (6,11) (1,22) 
28 8 (6,11) (1,23) 8 (6,11) (1,23) 8 (6,11) (1,23) 
29 8 (5,11) (1,22) 8 (5,11) (1,22) 8 (6,11) (1,22) 
30 8 (6,11) (1,20) 8 (6,11) (1,20) 9 (6,11) (1,21) 
31 9 (6,11) (1,21) 9 (6,11) (1,21) 9 (6,12) (1,21) 
32 9 (6,11.75) (1,23) 9 (6,11) (1,23) 9 (6,12) (1,23) 
33 8 (5,11) (1,21) 8 (5,11) (1,21) 9 (5,12) (1,22) 
34 8 (5,11) (1,23) 8 (5,11) (1,23) 8 (5,12) (1,24) 
35 8 (5,11) (1,19) 8 (5,11) (1,19) 8 (5,12) (1,19) 
36 8 (5,11) (1,19) 8 (5,11) (1,19) 8 (5,12) (1,19) 
37 8 (5,11) (1,19) 8 (5,11) (1,19) 8 (5,11) (1,18) 
38 8 (5,11) (1,19) 8 (5,11) (1,18) 8 (5,11) (1,18) 
39 7 (4,11) (1,18) 7 (4,11) (1,18) 8 (4,11) (1,19) 
40 7 (4,10) (1,19) 7 (4,10) (1,19) 7 (4.5,11) (1,18) 
41 7 (4,10) (1,18) 7 (4,10) (1,18) 7 (5,11) (1,18) 
42 7 (4,10) (1,17) 7 (4,10) (1,17) 7 (4,10) (1,17) 
43 7 (4,10) (1,18) 7 (4,10) (1,18) 7 (4,10) (1,18) 
44 7 (5,10) (1,19) 7 (5,10) (1,19) 7 (5,11) (1,19) 
45 7 (5,10) (1,20) 7 (5,10) (1,20) 7 (5,10) (1,20) 
46 7 (5,10) (1,18) 7 (5,10) (1,18) 7 (5,10) (1,18) 
47 7 (5,10) (1,19) 7 (5,10) (1,19) 8 (5,10) (1,18) 
48 7 (5,10) (1,20) 7 (5,10) (1,20) 8 (5,10.5) (1,20) 
49 8 (5,11) (1,21) 8 (5,11) (1,21) 8 (5,11) (1,20) 
50 8 (5,11) (1,16) 8 (5,11) (1,16) 8 (5,11) (1,16) 
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Supplementary Table 3. Results from the holdout data. Comparison between predicted survival probabilities from the final 
model and numbers of survivors and deaths within 2, 5 and 10 years from landmark ages 20, 30, 40 and 50. For 2-, 5-, and 
10-year survival we excluded those who were censored before 2, 5 and 10 years of follow-up respectively. Note that due to 
small numbers in some predicted probability groups we do not expect the observed percentages surviving to exactly match 
the predicted survival probabilities.  
  2-year survival 5-year survival 10-year survival 
Landmark 
age 
Probability of 
2-year, 5-year 
or 10-year 
survival from 
final model 
No. (%) 
who 
survived 2 
years 
No. (%) 
who died 
within 2 
years 
No. (%). 
who 
survived 5 
years 
No. (%) 
who died 
within 5 
years 
No. (%) 
who 
survived 10 
years 
No. (%) 
who died 
within 10 
years 
20 [0,0.7]  4 (57%)   3 (43%)   13 (48%)   14 (52%)   8 (20%)   32 (80%)   
 (0.7,0.9]  43 (90%)   5 (10%)   51 (78%)   14 (22%)   13 (50%)   13 (50%)   
 (0.9,0.95]  43 (93%)   3 (7%)   50 (94%)   3 (6%)   8 (73%)   3 (27%)   
 (0.95,1]  341 (99%)   3 (1%)   166 (98%)   3 (2%)   15 (83%)   3 (17%)  
        
30 [0,0.7]  2 (50%)   2 (50%)   5 (25%)   15 (75%)   3 (10%)   26 (90%)   
 (0.7,0.9]  22 (73%)   8 (27%)   27 (73%)   10 (27%)   5 (28%)   13 (72%)   
 (0.9,0.95]  37 (95%)   2 (5%)   21 (84%)   4 (16%)   4 (57%)   3 (43%)   
 (0.95,1]  160 (99%)   2 (1%)   63 (97%)   2 (3%)   3 (75%)   1 (25%)   
        
40 [0,0.7]  0 (0%)   1 (100%)   0 (0%)   5 (100%)   2 (14%)   12 (86%)   
 (0.7,0.9]  5 (71%)   2 (29%)   17 (74%)   6 (26%)   1 (50%)   1 (50%)   
 (0.9,0.95]  11 (100%)   0 (0%)   10 (100%)   0 (0%)   1 (100%)   0 (0%)   
 (0.95,1]  81 (99%)   1 (1%)   31 (100%)   0 (0%)   0  0  
        
50 [0,0.7]  3 (100%)   0 (0%)   1 (25%)   3 (75%)   0 (0%)   5 (100%)   
 (0.7,0.9]  5 (71%)   2 (29%)   4 (67%)   2 (33%)   0 (0%)   2 (100%)   
 (0.9,0.95]  8 (89%)   1 (11%)   5 (100%)   0 (0%)   1 (100%)   0 (0%)   
 (0.95,1]  20 (100%)   0 (0%)   4 (100%)   0 (0%)   1 (100%)   0 (0%)   
 [0,0.7]       
 
Supplementary Table 4. Overall C-Indexes and Brier scores for prediction of 2-year, 5-year and 10-year survival from a 
model including FEV1% as the only predictor and from a model including two treatment variables in addition to the 16 
predictors included in the final model  (Model 2 in Table 4 of the main text).  
 Results from the final 
model (Model 2: Table 4 
of the main text) 
Model using FEV1% 
predicted as the only 
predictora 
Additionally including 
two treatment 
variables in Model 2b 
 C-Index Brier score C-Index Brier score C-Index Brier score 
2-year survival 0.873 0.036 0.842 0.038 0.876 0.035 
5-year survival 0.843 0.076 0.813 0.081 0.844 0.075 
10-year survival 0.804 0.133 0.775 0.141 0.805 0.133 
a We repeated the final model with FEV1% predicted as the only predictor. Other features of the model were as in Model 2. 
b We assessed the impact on predictive performance of including two treatments that were included in the model of Nkam et 
al for the French Registry: use of oxygen therapy and use of non-invasive ventilation.16 Nkam et al also investigated use of 
oral corticosteroids, but there was insufficient data on use of this treatment in the UK data. We created binary variables at 
each landmark age, which indicate whether an individual had ever used each treatment in the past. The adjusted hazard ratio 
associated with oxygen use was 1.75 (95% CI 1.50-2.05) and the adjusted hazard ratio associated with non-invasive 
ventilation is 1.15 (95% CI 0.92-1.43). Therefore both oxygen therapy and non-invasive ventilation are associated with an 
increased mortality hazard (though the association for non-invasive ventilation is not statistically significant), because these 
treatments are used by sicker patients. The estimates do not have a causal interpretation. 
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Supplementary Figure 2. Comparison of landmark-age-specific C-indexes for 2-year, 5-year and 10-year survival from 
Model 1 (separate models from each landmark age) and Model 2 (supermodel).  
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Supplementary Figure 3. Comparison of landmark-age-specific Brier scores for 2-year, 5-year and 10-year survival from 
Model 1 (separate models from each landmark age) and Model 2 (supermodel).  
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Supplementary Figure 4. Predicted survival curves from landmark age 20 for example 
individuals in groups defined by 5-year survival probabilities. For individuals in the Registry 
at age 20 between 2013 and 2015 we obtained their predicted 5-year survival probabilities 
and categorized into groups with 5-year survival probabilities <0.5, (0.5,0.7,], (0.7,0.8], 
(0.8,0.9], (0.9,0.95], (0.95,0.99], (0.99, 1]. An example individual was created for each group.  
(i) Characteristics of example individualsa in groups defined by 5-year survival probability.  
5-year survival probability group <0.5 (0.5,0.7] (0.7,0.8] (0.8,0.9] (0.9,0.95] (0.95,0.99] (0.99,1] 
Example person 1 2 3 4 5 6 7 
Males, Femalesb        
Genotype (no. copies of F508del) 1, 2 2 2 2 2 2 1 
Age of diagnosis (years) 0  0   0   0   0   0   1, 3   
FEV1%  22, 26  28, 35   43, 39   44, 51   59, 61   78, 70   97, 98   
FVC%  32, 39   48. 53   58, 54   64, 72   75, 77   90, 90   103, 106   
Weight (kg)  48, 46   53, 47   51, 49   56, 48   57, 53   65, 56   73, 64   
Height (cm)  167, 159   169, 156   167, 160   174, 158   170, 158   173, 161   177, 164   
P. aeruginosa Yes Yes Yes Yes Yes Yes No 
B. cepacia No No No No No No No 
S. aureus No Yes, No Yes, No No Yes, No No No 
MRSA No No No No No No No 
Pancreatic insufficiency Yes Yes Yes Yes Yes Yes Yes 
CF related diabetes Yes Yes Yes No, Yes No No No 
Hospitalisation (not for IVs) No No No No No No No 
Number of hospital IV days 29+  15-28, 29+ 29+, 1-14 1-14, 15-28 0  0  0  
Number of hospital IV days 0 1-14, 29+ 0 0, 1-14 0 0 0 
aWe created an example individual for each group using the median values of the continuous predictors and the most 
common value of each categorical variable within that group. For hospital and home IV days we obtained the median 
number of days and then assigned the relevant category. This was done separately for males and females. 
b Values are shown as ‘male, female’, except were the value for males and females was the same. 
(ii) Predicted survivor curves based on the final model for example individuals with characteristics shown in the table above. 
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Supplementary Figure 5. Predicted survival curves from landmark age 40 for example 
individuals in groups defined by 5-year survival probabilities. For individuals in the Registry 
at age 40 between 2013 and 2015 we obtained their predicted 5-year survival probabilities 
and categorized into groups with 5-year survival probabilities <0.5, (0.5,0.7,], (0.7,0.8], 
(0.8,0.9], (0.9,0.95], (0.95,0.99], (0.99, 1]. An example individual was created for each group.  
(i) Characteristics of example individualsa in groups defined by 5-year survival probability. Results are not shown for groups 
of less than 5 individuals.  
5-year survival probability group <0.5 (0.5,0.7] (0.7,0.8] (0.8,0.9] (0.9,0.95] (0.95,0.99] (0.99,1] 
Example person 1 2 3 4 5 6 7 
Males, Femalesb        
Genotype (no. copies of F508del) - 2 2 2,1 2,1 1 1 
Age of diagnosis (years) -  2, 0  1, 0   1, 4   3, 3   2, 14   29, 13   
FEV1% -  27, 25   31, 28   38, 41   51, 47   68, 65   92, 92   
FVC% -  42, 43   60, 45   64, 59   70, 66   93, 81   97, 96   
Weight (kg) -  67   64   63   68   75   85   
Height (cm) -  173   170   173   176   176   175   
P. aeruginosa - Yes Yes Yes Yes Yes No 
B. cepacia - No No No No No No 
S. aureus - No No No No No No, Yes 
MRSA - No No No No No No 
Pancreatic insufficiency - Yes Yes Yes Yes Yes No 
CF related diabetes - Yes Yes Yes No, Yes No No 
Hospitalisation (not for IVs) - No No No No No No 
Number of hospital IV days - 29+ 15-28, 1-14 1-14 0, 1-14  0  0  
Number of hospital IV days - 29+, 1-14 0, 1-14 0 0 0 0 
aWe created an example individual for each group using the median values of the continuous predictors and the most 
common value of each categorical variable within that group. For hospital and home IV days we obtained the median 
number of days and then assigned the relevant category. This was done separately for males and females. 
b Values are shown as ‘male, female’, except were the value for males and females was the same. 
 (ii) Predicted survivor curves based on the final model for example individuals with characteristics shown in the table 
above. 
  
 
 
  
37 
 
Supplementary Figure 6. Predicted survival curves from landmark age 50 for example 
individuals in groups defined by 5-year survival probabilities. For individuals in the Registry 
at age 50 between 2013 and 2015 we obtained their predicted 5-year survival probabilities 
and categorized into groups with 5-year survival probabilities <0.5, (0.5,0.7,], (0.7,0.8], 
(0.8,0.9], (0.9,0.95], (0.95,0.99], (0.99, 1]. An example individual was created for each group.  
(i) Characteristics of example individualsa in groups defined by 5-year survival probability. Results are not shown for groups 
of less than 5 individuals. 
5-year survival probability group <0.5 (0.5,0.7] (0.7,0.8] (0.8,0.9] (0.9,0.95] (0.95,0.99] (0.99,1] 
Example person 1 2 3 4 5 6 7 
Males/Femalesb        
Genotype (no. copies of F508del) - 1, 2 2, - 2, 1 2, 1 1 1, - 
Age of diagnosis (years) -  4, 1   4, -   1   6, 28   28, 34   39, -   
FEV1% -  31, 30   27, -   48, 49   55, 64   82, 76   113, -  
FVC% -  51, 64   63, -   72, 69   76, 81   91, 90   108, -   
Weight (kg) -  65, 55   76, -   76, 61   80, 66   79, 65   86, -   
Height (cm) -  172, 158   174, -   17, 165   176, 162   176, 163   177, -   
P. aeruginosa - Yes Yes, - Yes No, Yes No No, - 
B. cepacia - No No, - No No No No, - 
S. aureus - No No, - No No No No, - 
MRSA - No No, - No No No No, - 
Pancreatic insufficiency - Yes Yes, - Yes Yes Yes, No No, - 
CF related diabetes - Yes Yes, - Yes, No No No No, - 
Hospitalisation (not for IVs) - No No, - No No No No, - 
Number of hospital IV days - 1-14 1-14, - 0 0  0  0, -  
Number of hospital IV days - 0 1-14, - 0 1-14 0 0, - 
aWe created an example individual for each group using the median values of the continuous predictors and the most 
common value of each categorical variable within that group. For hospital and home IV days we obtained the median 
number of days and then assigned the relevant category. This was done separately for males and females. 
b Values are shown as ‘male, female’, except were the value for males and females was the same. 
 (ii) Predicted survivor curves based on the final model for example individuals with characteristics shown in the table 
above. 
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Supplementary Figure 7. [This is a colour version of Figure 2 in the main text.] Calibration 
plots using the final model (Model 2) for prediction of 2-year, 5-year and 10-year survival 
from landmark ages 20, 30, 40 and 50. The vertical axis shows the mean model-based x-year 
survival probability (x=2,5,10) in quintiles of the model-based probabilities. The horizontal 
axis shows the mean x-year survival probability obtained using Kaplan-Meier estimates in 
quintiles of the model-based probabilities. The five points have been joined by a line. 
  
  
 
Supplementary Figure 8. [This is a colour version of Figure 4 in the main text.] Plots 
showing the distribution of 2-, 5- and 10-year survival probabilities from landmark ages 20, 
30, 40 and 50 for individuals in the Registry at those ages between 2013 and 2015.  
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